US approves updated Pfizer, Moderna shots targeting Omicron / Photo: Joseph Prezioso - AFP/File
RBGPF
0.0000
Zürcher Nachrichten - US approves updated Pfizer, Moderna shots targeting Omicron
EUR
-
AED 4.241201
AFN 76.219915
ALL 93.210974
AMD 421.7986
AOA 1060.156793
ARS 1727.958172
AUD 1.63908
AWG 2.081626
AZN 1.959559
BAM 1.954403
BBD 2.32254
BDT 142.738005
BHD 0.43488
BIF 3440.896583
BMD 1.154855
BND 1.478624
BOB 14.004993
BRL 5.916207
BSD 1.153151
BTN 109.628664
BWP 15.63742
BYN 3.410563
BYR 22635.15384
BZD 2.319233
CAD 1.618125
CDF 2611.126427
CHF 0.932311
CLF 0.026733
CLP 1055.559908
CNY 7.795147
CNH 7.793913
COP 3675.544784
CRC 522.915026
CUC 1.154855
CUP 30.603652
CVE 110.186265
CZK 24.201154
DJF 205.338828
DKK 7.47541
DOP 67.250199
DZD 153.530983
EGP 57.54318
ERN 17.322822
ETB 186.117873
FJD 2.553963
FKP 0.857848
GBP 0.857774
GEL 3.019946
GGP 0.857848
GHS 13.520339
GIP 0.857848
GMD 84.878181
GNF 10128.411837
GTQ 8.795715
GYD 241.227629
HKD 9.058306
HNL 30.907112
HRK 7.534038
HTG 150.767698
HUF 362.223087
IDR 20682.294394
ILS 3.477385
IMP 0.857848
INR 109.932764
IQD 1510.627108
IRR 1587694.361999
ISK 141.792902
JEP 0.857848
JMD 183.243508
JOD 0.818791
JPY 182.181232
KES 149.439303
KGS 100.991685
KHR 4673.518854
KMF 493.12343
KRW 1638.640772
KWD 0.357023
KYD 0.961017
KZT 541.135669
LAK 26067.486096
LBP 103263.512096
LKR 386.906578
LRD 208.141271
LSL 18.917964
LTL 3.409986
LVL 0.69856
LYD 7.339597
MAD 10.74762
MDL 20.03577
MGA 4908.365176
MKD 61.481068
MMK 2424.552772
MNT 4152.673297
MOP 9.316283
MRU 46.240358
MUR 54.209096
MVR 17.842347
MWK 1999.510632
MXN 19.917775
MYR 4.721853
MZN 73.807157
NAD 18.917964
NGN 1572.381111
NIO 42.438205
NOK 11.00856
NPR 175.401109
NZD 1.964222
OMR 0.444037
PAB 1.153176
PEN 3.903611
PGK 5.170149
PHP 70.148769
PKR 320.189388
PLN 4.30117
PYG 6876.93715
QAR 4.215887
RON 5.244777
RSD 117.358631
RUB 93.515578
RWF 1693.938243
SAR 4.333626
SBD 9.317771
SCR 16.99798
SDG 693.483603
SEK 10.953417
SGD 1.479663
SLE 28.408276
SOS 659.009126
SRD 43.501064
STD 23903.162464
STN 24.481764
SVC 10.089834
SZL 18.902002
THB 38.159872
TJS 10.643495
TMT 4.041992
TND 3.383582
TRY 54.964638
TTD 7.82126
TWD 37.289687
TZS 3055.166026
UAH 51.602087
UGX 4300.926733
USD 1.154855
UYU 46.366868
UZS 13708.204675
VES 871.004473
VND 30288.376519
VUV 137.825311
WST 3.151849
XAF 655.468764
XAG 0.018606
XAU 0.000271
XCD 3.121053
XCG 2.078224
XDR 0.815196
XOF 655.474435
XPF 119.331742
YER 273.556256
ZAR 18.867557
ZMK 10395.078432
ZMW 22.01327
ZWL 371.86277
- Stocks mixed with tech firms back under pressure
- New Australia coach Kiss gives Japan starts to Ross, Amatosero
- How Blundell's old school tactic ended England's 'Bazball' era
- 'Stretch our money': Romanians face highest EU inflation
- Israel reports troop deaths as Lebanon talks underway in Rome
- Iran says close to Hormuz plan with Oman, but reopening depends on US
- Seeds Rybakina, Pegula, Gauff reach third round at WTA Toronto
- Messi scores twice to set Leagues Cup record in Miami victory
- Police raid South Korea FA in probe into World Cup coach appointment
- Asian stocks mostly down with tech firms back under pressure
US approves updated Pfizer, Moderna shots targeting Omicron
US health officials on Wednesday authorized updated Covid-19 vaccinations by Moderna and Pfizer-BioNTech that specifically target the latest strains of the Omicron variant, with the goal of jump-starting a new booster campaign.
The two updated booster shots aimed at providing "better protection against Covid-19 caused by the Omicron variant" are approved for people age 12 and above for the Pfizer shot and 18 and older for Moderna, the Food and Drug Administration (FDA) said in a statement.
This new generation of anti-Covid vaccines targets both the original strain of coronavirus and the BA.4 and BA.5 lineages, the subvariants of Omicron that are causing the most cases in the United States and which the FDA predicts will circulate in the coming months.
Earlier this summer the US health department announced it had purchased 105 million doses from Pfizer and 66 million from Moderna for use over the fall and winter.
The vaccines have yet to be recommended by the Centers for Disease Control and Prevention, the nation's health protection agency. But an independent panel of experts is scheduled to be convened by the CDC on Thursday to discuss the updates.
CDC director Rochelle Walensky will be in charge of giving the final green light.
The new versions of the vaccines could potentially be available in the United States as early as next week.
"Receiving a booster that specifically targets the Omicron BA.4/.5 variant, currently the most prevalent strain of SARS-CoV-2, is an important public health measure that people can take to help protect themselves, especially as we head into a season filled with indoor gatherings," Moderna chief executive Stephane Bancel said in a statement.
The vaccines currently in circulation target the initial strain of the virus that first appeared in Wuhan, China. But they have gradually proven to be less effective against the variants that have appeared over time, due to rapid evolution of the virus.
In contrast to the Alpha and Delta variants, which eventually waned, Omicron and its subvariants have come to dominate infections worldwide in 2022.
Pfizer and Moderna have also filed for approval of their updated vaccines with the European Medicines Agency.
J.Hasler--NZN
